Bifogade filer
Kurs
-1,78%
Likviditet
627 MDKK
Kalender
Tid* | ||
2025-08-13 | N/A | Kvartalsrapport 2025-Q2 |
2025-04-03 | N/A | Årsstämma |
2025-02-26 | N/A | Bokslutskommuniké 2024 |
2024-08-30 | - | X-dag halvårsutdelning NSIS B 2 |
2024-08-29 | - | X-dag kvartalsutdelning NSIS B 2 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-01 | - | X-dag kvartalsutdelning NSIS B 2 |
2024-05-01 | - | X-dag halvårsutdelning NSIS B 2 |
2024-04-30 | - | Årsstämma |
2024-03-04 | - | Extra Bolagsstämma 2024 |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-10-13 | - | X-dag bonusutdelning NSIS B 4.2 |
2023-10-11 | - | X-dag bonusutdelning NSIS B 4.2 |
2023-08-09 | - | Kvartalsrapport 2023-Q2 |
2023-04-26 | - | Kvartalsrapport 2023-Q1 |
2023-03-30 | - | Extra Bolagsstämma 2023 |
2023-03-03 | - | X-dag ordinarie utdelning NSIS B 6.00 DKK |
2023-03-02 | - | Årsstämma |
2023-01-26 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-11 | - | Kvartalsrapport 2022-Q2 |
2022-04-27 | - | Kvartalsrapport 2022-Q1 |
2022-03-17 | - | X-dag ordinarie utdelning NSIS B 5.50 DKK |
2022-03-16 | - | Årsstämma |
2022-02-01 | - | Bokslutskommuniké 2021 |
2021-10-27 | - | Kvartalsrapport 2021-Q3 |
2021-08-12 | - | Kvartalsrapport 2021-Q2 |
2021-04-27 | - | Kvartalsrapport 2021-Q1 |
2021-03-12 | - | X-dag ordinarie utdelning NSIS B 5.25 DKK |
2021-03-11 | - | Årsstämma |
2021-02-02 | - | Bokslutskommuniké 2020 |
2020-10-21 | - | Kvartalsrapport 2020-Q3 |
2020-08-12 | - | Kvartalsrapport 2020-Q2 |
2020-04-29 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | X-dag ordinarie utdelning NSIS B 5.25 DKK |
2020-02-26 | - | Årsstämma |
2020-01-23 | - | Bokslutskommuniké 2019 |
2019-10-23 | - | Kvartalsrapport 2019-Q3 |
2019-08-08 | - | Kvartalsrapport 2019-Q2 |
2019-04-24 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | X-dag ordinarie utdelning NSIS B 5.00 DKK |
2019-02-27 | - | Årsstämma |
2019-01-24 | - | Bokslutskommuniké 2018 |
2018-10-24 | - | Kvartalsrapport 2018-Q3 |
2018-08-10 | - | Kvartalsrapport 2018-Q2 |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-03-14 | - | X-dag ordinarie utdelning NSIS B 4.50 DKK |
2018-03-13 | - | Årsstämma |
2018-02-07 | - | Bokslutskommuniké 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-08-11 | - | Kvartalsrapport 2017-Q2 |
2017-04-26 | - | Kvartalsrapport 2017-Q1 |
2017-02-23 | - | X-dag ordinarie utdelning NSIS B 4.00 DKK |
2017-02-22 | - | Årsstämma |
2017-01-18 | - | Bokslutskommuniké 2016 |
2016-10-26 | - | Kvartalsrapport 2016-Q3 |
2016-08-10 | - | Kvartalsrapport 2016-Q2 |
2016-04-20 | - | Kvartalsrapport 2016-Q1 |
2016-02-25 | - | X-dag ordinarie utdelning NSIS B 3.50 DKK |
2016-02-24 | - | Årsstämma |
2016-01-19 | - | Bokslutskommuniké 2015 |
2015-10-22 | - | Kvartalsrapport 2015-Q3 |
2015-08-06 | - | Kvartalsrapport 2015-Q2 |
2015-04-23 | - | Kvartalsrapport 2015-Q1 |
2015-02-26 | - | X-dag ordinarie utdelning NSIS B 3.00 DKK |
2015-02-25 | - | Årsstämma |
2015-01-20 | - | Bokslutskommuniké 2014 |
2014-10-23 | - | Kvartalsrapport 2014-Q3 |
2014-08-14 | - | Kvartalsrapport 2014-Q2 |
2014-04-24 | - | Kvartalsrapport 2014-Q1 |
2014-02-27 | - | X-dag ordinarie utdelning NSIS B 2.50 DKK |
2014-02-26 | - | Årsstämma |
2014-01-21 | - | Bokslutskommuniké 2013 |
2013-10-25 | - | Kvartalsrapport 2013-Q3 |
2013-08-09 | - | Kvartalsrapport 2013-Q2 |
2013-04-25 | - | Kvartalsrapport 2013-Q1 |
2013-03-01 | - | X-dag ordinarie utdelning NSIS B 2.20 DKK |
2013-02-28 | - | Årsstämma |
2012-10-25 | - | Kvartalsrapport 2012-Q3 |
2012-08-16 | - | Kvartalsrapport 2012-Q2 |
2012-04-25 | - | Kvartalsrapport 2012-Q1 |
2012-03-01 | - | X-dag ordinarie utdelning NSIS B 1.90 DKK |
2012-02-29 | - | Årsstämma |
2012-01-19 | - | Bokslutskommuniké 2011 |
2011-11-28 | - | Split NSIS B 1:5 |
2011-10-28 | - | Kvartalsrapport 2011-Q3 |
2011-08-11 | - | Kvartalsrapport 2011-Q2 |
2011-04-29 | - | Kvartalsrapport 2011-Q1 |
2011-03-03 | - | X-dag ordinarie utdelning NSIS B 8.00 DKK |
2011-03-02 | - | Årsstämma |
2011-01-21 | - | Bokslutskommuniké 2010 |
2010-10-28 | - | Kvartalsrapport 2010-Q3 |
2010-08-12 | - | Kvartalsrapport 2010-Q2 |
2010-04-29 | - | Kvartalsrapport 2010-Q1 |
2010-03-04 | - | X-dag ordinarie utdelning NSIS B 5.75 DKK |
2010-03-03 | - | Årsstämma |
2009-03-05 | - | X-dag ordinarie utdelning NSIS B 5.25 DKK |
2008-03-06 | - | X-dag ordinarie utdelning NSIS B 5.00 DKK |
2007-03-09 | - | X-dag ordinarie utdelning NSIS B 4.50 DKK |
2006-03-02 | - | X-dag ordinarie utdelning NSIS B 4.00 DKK |
2005-03-17 | - | X-dag ordinarie utdelning NSIS B 3.50 DKK |
2004-03-18 | - | X-dag ordinarie utdelning NSIS B 3.15 DKK |
2003-03-20 | - | X-dag ordinarie utdelning NSIS B 2.25 DKK |
2002-03-21 | - | X-dag ordinarie utdelning NSIS B 2.00 DKK |
2001-03-22 | - | X-dag ordinarie utdelning NSIS B 1.65 DKK |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Bioteknik |
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
February 2, 2024 Company announcement No. 07 |
On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination") was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024. As previously announced, the name of the combined company will be Novonesis.
Settlement of the Combination completed
The settlement of the Combination has now been successfully completed by the exchange of all shares of Chr. Hansen for 187,298,646 new Novozymes B-shares of nominally DKK 2 each (374,597,292 new Novozymes B-shares of nominally DKK 1) (the "Merger Consideration Shares") under the existing ISIN code DK0060336014 and the cash payment in lieu of fractional entitlements to Merger Consideration Shares via Euronext Securities Copenhagen has been initiated.
Eligible former shareholders of Chr. Hansen (the "Chr. Hansen Shareholders"), excluding Novo Holdings A/S ("Novo Holdings"), have received 1.5326 Merger Consideration Shares in exchange for each Chr. Hansen share that they held, and Novo Holdings has received 1.0227 Merger Consideration Shares in exchange for each Chr. Hansen share held with respect to Novo Holdings' holding of 28,983,112 Chr. Hansen shares and 1.5326 Merger Consideration Shares in exchange for each Chr. Hansen share held exceeding 28,983,112.
The Merger Consideration Shares issued have been admitted to trading and official listing on Nasdaq Copenhagen A/S on January 31, 2024, under the symbol "NZYM B" and the permanent ISIN code DK0060336014.
Chr. Hansen Shareholders restricted from receiving shares in the Combination
As further described in the exemption document, certain Chr. Hansen Shareholders with a registered address in, or who are resident or otherwise located in, or who are organized under the laws of certain jurisdictions, the ability to participate in the Combination and receive new B-shares has been restricted by the laws of such other jurisdictions (each a "Restricted Shareholder").
For such Restricted Shareholders only, the combined company will procure that the new B-shares that would otherwise be attributable to such Restricted Shareholders will be sold by Nordea Danmark, Filial af Nordea Bank Abp, Finland acting on behalf of the combined company, in a vendor placement (via Nasdaq Copenhagen or other trading venues in one or more tranches and outside the U.S. and other restricted jurisdictions) (the "Vendor Placement") and the cash proceeds from the Vendor Placement will be distributed in DKK to the Restricted Shareholders via a corporate action in Euronext as soon as practicably possible following completion of the Vendor Placement. Other shareholders in the combined company cannot participate in the Vendor Placement.
For further information on the Vendor Placement, reference is made to the exemption document available at www.power-with-biology.com.
Transaction website
For additional information, visit www.power-with-biology.com.
Contact information | ||
Investor Relations | ||
Tobias Bjorklund | +45 3077 8682 | tobb@novonesis.com |
Anders Enevoldsen | +45 5350 1453 | adev@novonesis.com |
Media Relations | ||
Lina Danstrup | +45 3077 0552 | lind@novonesis.com |